FIRST-LINE MARIBAVIR TREATMENT FOR PATIENTS WITH CMV INFECTION INTOLERANT TO CONVENTIONAL ANTIVIRAL DRUGS (EHA 2026) - May 13, 2026 - Abstract #EHA-2418; PB4055; "All of the patients received CMV prophylaxis with letermovir for 100 days and only one patient had a breakthrough infection while still receiving it...The remaining two patients did not respond to multiple lines of therapy, including valganciclovir, foscarnet, cidofovir, and maribavir...Drug resistance testing by next-generation sequencing was not performed. Summary/Conclusion Maribavir is an effective and safe treatment option for CMV infection in patients with neutropenia and/or renal impairment after allogeneic stem cell transplantation."
Clinical • Acute Graft versus Host Disease • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Neutropenia
|
|
Andrej Pešić 1; Nevena Bešević 1; Milena Todorovic Balint 1,2
|